We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amedisys Buys 6 Home Health, Hospice Care Centers from Tenet
Read MoreHide Full Article
Baton Rouge, LA-based Amedisys Inc. (AMED - Free Report) , a household name in home health and hospice services space, recently signed an exclusive agreement with Tenet Healthcare Corporation (THC). Per the deal, the former will acquire six of Tenet’s home health care centers and Hospice operations in Arizona, Illinois, Massachusetts and Texas.
Tenet Healthcare is a diversified healthcare services company that offers technology-based health management solutions to hospitals, health systems, integrated delivery networks, physician groups, self-insured organizations and health plans.
Amedisys claims that the impending buyout is a strategic fit as it will give the company a better opportunity to continue with its goal of providing high-quality post-acute services in key markets. The consolidation will allow Amedisys to improve the delivery of care and management of patients across the care continuum in these markets.
In the last reported fourth-quarter 2016, the company decided to acquire another home healthcare company known as Home Staff, LLC.
In this regard, Amedisys’ long-term strategy is to evolve from being a traditional home health and hospice care company to one focused on bringing home a range of care to address the needs of patients. As a result, the company is developing and acquiring new business lines that will complement its existing home care and hospice business and help aged people manage their health more effectively and stay at their homes longer. It is also working to develop or acquire new business lines that are focused on managing patients’ age-related disease processes from the onset till the end of life.
According to a recent report by MarketsandMarkets, the global home healthcare and hospice market is forecasted to reach a worth of $349.8 billion by 2020, at a CAGR of 9.0%. Growth will mainly be driven by factors such as rising old-age demography across the globe, growing need of cost-effective healthcare, rising incidences of chronic diseases and technological advancements in devices.
However, changing reimbursement policies, limited insurance coverage and risks to personal safety of home care workers are the factors restraining growth in the home healthcare market to a certain extent. The recent proposed rule for U.S. Home Health in 2017 by CMS, which includes a shift to a budget neutral plan for reimbursement, may affect home health care companies. Despite the persistent pressure on the U.S. healthcare system, Amedisys will continue to benefit from the above-mentioned strengths in the home-health care and hospice market.
Stock Performance
Amedisys has been performing well for quite some time. In the last three months, the company has been trading above the Zacks categorized Medical - Outpatient and Home Healthcare industry. The stock has gained 32% over the time frame, compared to the the broader industry’s addition of only 7.3%.
Notably, in the recently concluded fourth quarter of 2016, the company witnessed strong organic growth in Medicare and non-Medicare revenues under its Home Health division. The division grew 2.2% year over year to $268.3 million. Within the Hospice division, net service revenues grossed $85.2 million, up 12.4% year over year.
Glaukos gained over 100% in the last one year in comparison to the S&P 500’s gain of 20.2%. The company has a stellar four-quarter average earnings surprise of over 100%.
Cardiovascular Systems surged over 100% in the last one year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 67.8%.
Neogen gained 27.9% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared to the industry average of 15.2%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amedisys Buys 6 Home Health, Hospice Care Centers from Tenet
Baton Rouge, LA-based Amedisys Inc. (AMED - Free Report) , a household name in home health and hospice services space, recently signed an exclusive agreement with Tenet Healthcare Corporation (THC). Per the deal, the former will acquire six of Tenet’s home health care centers and Hospice operations in Arizona, Illinois, Massachusetts and Texas.
Tenet Healthcare is a diversified healthcare services company that offers technology-based health management solutions to hospitals, health systems, integrated delivery networks, physician groups, self-insured organizations and health plans.
Amedisys claims that the impending buyout is a strategic fit as it will give the company a better opportunity to continue with its goal of providing high-quality post-acute services in key markets. The consolidation will allow Amedisys to improve the delivery of care and management of patients across the care continuum in these markets.
Amedisys Inc Price
Amedisys Inc Price | Amedisys Inc Quote
In the last reported fourth-quarter 2016, the company decided to acquire another home healthcare company known as Home Staff, LLC.
In this regard, Amedisys’ long-term strategy is to evolve from being a traditional home health and hospice care company to one focused on bringing home a range of care to address the needs of patients. As a result, the company is developing and acquiring new business lines that will complement its existing home care and hospice business and help aged people manage their health more effectively and stay at their homes longer. It is also working to develop or acquire new business lines that are focused on managing patients’ age-related disease processes from the onset till the end of life.
According to a recent report by MarketsandMarkets, the global home healthcare and hospice market is forecasted to reach a worth of $349.8 billion by 2020, at a CAGR of 9.0%. Growth will mainly be driven by factors such as rising old-age demography across the globe, growing need of cost-effective healthcare, rising incidences of chronic diseases and technological advancements in devices.
However, changing reimbursement policies, limited insurance coverage and risks to personal safety of home care workers are the factors restraining growth in the home healthcare market to a certain extent. The recent proposed rule for U.S. Home Health in 2017 by CMS, which includes a shift to a budget neutral plan for reimbursement, may affect home health care companies. Despite the persistent pressure on the U.S. healthcare system, Amedisys will continue to benefit from the above-mentioned strengths in the home-health care and hospice market.
Stock Performance
Amedisys has been performing well for quite some time. In the last three months, the company has been trading above the Zacks categorized Medical - Outpatient and Home Healthcare industry. The stock has gained 32% over the time frame, compared to the the broader industry’s addition of only 7.3%.
Notably, in the recently concluded fourth quarter of 2016, the company witnessed strong organic growth in Medicare and non-Medicare revenues under its Home Health division. The division grew 2.2% year over year to $268.3 million. Within the Hospice division, net service revenues grossed $85.2 million, up 12.4% year over year.
Zacks Rank & Key Picks
Amedisys currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical product sector are Glaukos Corporation (GKOS - Free Report) , Cardiovascular Systems and Neogen Corp. (NEOG - Free Report) . All these stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Glaukos gained over 100% in the last one year in comparison to the S&P 500’s gain of 20.2%. The company has a stellar four-quarter average earnings surprise of over 100%.
Cardiovascular Systems surged over 100% in the last one year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 67.8%.
Neogen gained 27.9% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared to the industry average of 15.2%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>